Qiagen QIA.DE
Qiagen is a Dutch company that develops and commercializes molecular diagnostics and life sciences technologies, offering testing kits and systems for clinical and research laboratories. Qiagen trades with solid financial health (ND/EBITDA 1.17x, liquidity 2.85) and a 26.32% operating margin, but revenue growth is flat (0.30%) and momentum is negative (12-1: -3.74), justifying average scores in growth and momentum.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Qiagen is a Dutch company that develops and commercializes molecular diagnostics and life sciences technologies, offering testing kits and systems for clinical and research laboratories. Qiagen trades with solid financial health (ND/EBITDA 1.17x, liquidity 2.85) and a 26.32% operating margin, but revenue growth is flat (0.30%) and momentum is negative (12-1: -3.74), justifying average scores in growth and momentum.
Score by category
| Category | Score |
|---|---|
| Financial health | 8.0 |
| Quality / Moat | 6.2 |
| Valuation | 5.7 |
| Growth | 5.1 |
| Dividend | 4.3 |
| Momentum | 3.0 |
| Risk & Context | 8.1 |
OVERALL SCORE: 6.1/10
Context and risks
No material exposure to the oil rally or specific geopolitical tensions. The molecular diagnostics business does not depend on supply routes in conflict zones or energy commodities.
News considered in the analysis
- Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now — Artículo de opinión de Zacks sin información nueva; reitera la tesis de mantener sin aportar datos concretos.
- Qiagen Shares Rise 4% Following Report of Private Equity Takeover Interest — Rumor de interés de compra por parte de capital privado; si se materializara, implicaría una prima sustancial sobre el precio de mercado. Aún no hay oferta formal.
- QIAGEN (QGEN) Rolls Out QIAsymphony Connect Following Q2 Outperformance — Lanzamiento de un nuevo producto (QIAsymphony Connect) que amplía la oferta de automatización de laboratorios; refuerza la posición competitiva a medio plazo.
- ILMN Stock Keeps Climbing. Should You Climb On? — Titular sobre Illumina, un competidor, sin implicación directa para Qiagen.
- Qiagen (QGEN) Beat Q2 Estimates And Reaffirmed Outlook, Is It Still Below Fair Value? — Resultados del segundo trimestre superiores a lo esperado y reafirmación de las previsiones; noticia ya conocida y reflejada en el precio.
Verdict: Hold: private equity takeover interest could offer a premium, but without a formal offer the stock remains anchored to its flat growth and a 22.66 P/E.
Main risk: Dependence on regulatory approval for new diagnostic products and increasing competition in the molecular testing space, which could compress margins despite the current 26.32% operating margin.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →